

Annette Bruchfeld

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7062567/annette-bruchfeld-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

4,097
citations

30
h-index

63
g-index

114
ext. papers

4,985
ext. citations

5.5
avg, IF

5.52
L-index

#	Paper	IF	Citations
99	Genetically distinct subsets within ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2012 , 367, 214-23	59.2	627
98	Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. <i>Lancet, The</i> , 2015 , 386, 1537-45	40	539
97	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 955-60	2.4	278
96	High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. <i>Hepatology</i> , 2005 , 41, 275-9	11.2	174
95	Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. <i>Molecular Medicine</i> , 2007 , 13, 210-5	6.2	143
94	Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. <i>American Journal of Kidney Diseases</i> , 2011 , 57, 566-74	7.4	131
93	Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 1573-80	4.3	119
92	Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 701-8	3.2	117
91	Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 316-21	3.4	111
90	Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study. <i>Journal of Viral Hepatitis</i> , 2001 , 8, 287-92	3.4	111
89	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 399-405	2.4	102
88	Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. <i>Transplantation</i> , 2004 , 78, 745-50	1.8	101
87	Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 84-7	3.4	81
86	MO358ACUTE KIDNEY INJURY AND MORTALITY RISK IN OLDER ADULTS WITH AND WITHOUT COVID-19: DATA FROM GEROCOVID STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36,	4.3	78
85	High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). <i>Molecular Medicine</i> , 2008 , 14, 109-15	6.2	76
84	Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. <i>Journal of Internal Medicine</i> , 2010 , 268, 94-101	10.8	64
83	Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. <i>Molecular Medicine</i> , 2012 , 18, 215-23	6.2	57

82	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1125-30	2.4	57
81	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 585-594	18.8	53
80	Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R36	5.7	53
79	Outcome and treatment of elderly patients with ANCA-associated vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1128-35	6.9	50
78	COVID-19 vaccines and kidney disease. <i>Nature Reviews Nephrology</i> , 2021 , 17, 291-293	14.9	50
77	Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. <i>American Journal of Nephrology</i> , 2014 , 39, 322-30	4.6	49
76	Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 215-8	3.2	48
75	Rituximab for minimal change disease in adults: long-term follow-up. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 851-6	4.3	45
74	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 84-91	4.3	44
73	High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis with renal manifestations. <i>Molecular Medicine</i> , 2011 , 17, 29-35	6.2	43
72	Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. <i>Molecular Medicine</i> , 2009 , 15, 70-5	6.2	43
71	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 719-27	4.3	35
70	Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. <i>International Journal of Artificial Organs</i> , 2007 , 30, 212-9	1.9	34
69	Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. <i>Journal of Hepatology</i> , 2018 , 68, 904-911	13.4	30
68	The COVID-19 pandemic: consequences for nephrology. <i>Nature Reviews Nephrology</i> , 2021 , 17, 81-82	14.9	28
67	Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. <i>Scandinavian Journal of Rheumatology</i> , 2012 , 41, 116-9	1.9	25
66	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	25
65	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , 2020 , 40, 1032-1041	7.9	23

64	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1243-1249	2.4	22
63	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. <i>Hepatology Research</i> , 2017 , 47, 1340-1345	5.1	21
62	Mild cognitive impairment and kidney disease: clinical aspects. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 10-17	4.3	21
61	Late-onset neutropenia after rituximab in ANCA-associated vasculitis. <i>Scandinavian Journal of Rheumatology</i> , 2016 , 45, 404-7	1.9	20
60	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1112-1114	4.3	19
59	Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. <i>American Journal of Nephrology</i> , 2009 , 29, 447-53	4.6	17
58	The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 3112-6	4.3	17
57	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis. <i>Nephron Clinical Practice</i> , 2014 , 128, 277-82		16
56	Macrophage Migration Inhibitory Factor in Clinical Kidney Disease. <i>Frontiers in Immunology</i> , 2016 , 7, 8	8.4	16
55	B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 20-26	4.5	16
54	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1684-1687.e10	11.5	15
53	ERA-EDTA invests in transformation to greener health care. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 901-903	4.3	14
52	Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. <i>International Journal of Artificial Organs</i> , 2007 , 30, 6-15	1.9	14
51	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102671	13.6	13
50	Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 2051-2057	4.3	13
49	Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease. <i>Kidney International Reports</i> , 2017 , 2, 1208-1218	4.1	10
48	Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 2059-2072	4.3	9
47	Acute kidney injury and mortality risk in older adults with COVID-19. <i>Journal of Nephrology</i> , 2021 , 34, 295-304	4.8	9

46	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021 , 6, 881-893	4.1	9
45	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 1758-1760	4.3	9
44	Cholinergic anti-inflammatory pathway activity in dialysis patients: a role for neuroimmunomodulation?. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 599-605	4.5	8
43	Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). <i>Molecular Medicine</i> , 2013 , 19, 109-114	6.2	8
42	Pegylated interferon and ribavirin in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 1444-5; author reply 1445-6	4.3	8
41	Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2020 , 47, 714-721	4.1	8
40	Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 920-925	4.3	7
39	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	7
38	The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation. <i>Molecular Medicine</i> , 2019 , 25, 39	6.2	6
37	Rituximab in minimal change disease and focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 983-985	4.3	6
36	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1469-1480	4.3	5
35	The cholinergic anti-inflammatory pathway in chronic kidney disease-review and vagus nerve stimulation clinical pilot study. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1840-1852	4.3	5
34	Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis. <i>Clinical Nephrology</i> , 2013 , 80, 388-94	2.1	5
33	The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum. <i>Autoimmunity Reviews</i> , 2021 , 20, 102986	13.6	5
32	Funding kidney research as a public health priority: challenges and opportunities. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	5
31	Microparticles expressing myeloperoxidase as potential biomarkers in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). <i>Journal of Molecular Medicine</i> , 2020 , 98, 1279-1286	5.5	4
30	Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	4
29	Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	4

28	Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia. <i>Journal of Hepatology</i> , 2006 , 44, 432-3; author reply 433	13.4	3
27	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 23-35	4.5	3
26	Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. <i>Seminars in Dialysis</i> , 2019 , 32, 135-140	2.5	3
25	Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	3
24	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1077-1082	4.3	3
23	First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 211	5.7	3
22	The nephrology crystal ball: the medium-term future. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 222-236	4.3	2
21	Rituximab for Multirelapsing, Steroid-Dependent or Steroid-Resistant, Minimal-Change Nephropathy – Report of Nine Adult Cases. <i>Nephrology Research & Reviews</i> , 2010 , 2, 8-11		2
20	Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia--anti-viral therapy vs rituximab. <i>Rheumatology</i> , 2006 , 45, 783-4; author reply 784-5	3.9	2
19	Nomenclature in nephrology: preserving RenalRand NephroRn the glossary of kidney health and disease. <i>Journal of Nephrology</i> , 2021 , 34, 639-648	4.8	2
18	Lancet Countdown paper: what does it mean for nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 4-6	4.3	2
17	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2020 , 47, 580-588	4.1	2
16	The COVID-19 Epidemic: Management and Outcomes of Hemodialysis and Peritoneal Dialysis Patients in Stockholm, Sweden. <i>Kidney and Blood Pressure Research</i> , 2021 , 46, 250-256	3.1	2
15	Brain dysfunction in tubular and tubulointerstitial kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	2
14	019. PENTRAXIN-3 PLASMA LEVELS AND GENE POLYMORPHISMS IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019 , 58,	3.9	1
13	Is There Decreasing Public Interest in Renal Transplantation? A Google Trends Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
12	C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.. <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 922-928	4.5	1
11	Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition?. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa056	1.1	1

10	Observational study of risk factors associated with clinical outcome among elderly kidney transplant recipients in Sweden - a decade of follow-up. <i>Transplant International</i> , 2021 , 34, 2363-2370	3	1
9	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry.. <i>Kidney360</i> , 2022 , 3, 293-306	1.8	1
8	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 437-442	4.5	0
7	HCV eradication in chronic kidney disease: ready for prime time?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 880-882	18.8	0
6	Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report. <i>European Heart Journal - Case Reports</i> , 2021 , 5, ytab151	0.9	0
5	Pentraxin-3 - a potential biomarker in ANCA-associated vasculitis.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-9	1.9	0
4	The Influence of C-Hepatitis on C-Reactive Protein in a Cohort of Brazilian Hemodialysis Patients. <i>Hemodialysis International</i> , 2004 , 8, 102-102	1.7	
3	Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations. <i>African Journal of Nephrology</i> , 2020 , 23, 159-168	0.8	
2	POS1230 OUTCOME FOLLOWING COVID-19 INFECTION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 898.2-898	2.4	
1	OP0003 AUTOREACTIVE CD4+ T CELLS AND THEIR TCR REPERTOIRE IN PR3-ANCA ASSOCIATED VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1.3-1	2.4	